Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Tesch H, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Hadji P, Janni W, Muth M, Kreuzeder J, Quiering C, Taran FA. Tesch H, et al. Among authors: quiering c. Int J Cancer. 2019 Feb 15;144(4):877-885. doi: 10.1002/ijc.31738. Epub 2018 Oct 30. Int J Cancer. 2019. PMID: 29992557 Free PMC article. Clinical Trial.
The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial.
Hadji P, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Janni W, Muth M, Kreuzeder J, Quiering C, Grischke EM, Tesch H. Hadji P, et al. Among authors: quiering c. J Bone Oncol. 2018 Oct 2;14:010-10. doi: 10.1016/j.jbo.2018.09.010. eCollection 2019 Feb. J Bone Oncol. 2018. PMID: 30515367 Free PMC article.
Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.
Reichardt P, Schlemmer M, Delgado Perez JR, Papai Z, Prausova J, Melichar B, Fumagalli E, Barone C, Bauer S, Pustowka A, Crippa S, Castellana R, Quiering C, Le Cesne A. Reichardt P, et al. Among authors: quiering c. Oncol Res Treat. 2019;42(12):629-635. doi: 10.1159/000502749. Epub 2019 Sep 24. Oncol Res Treat. 2019. PMID: 31550719 Clinical Trial.
Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study.
Feltgen N, Hattenbach LO, Bertelmann T, Callizo J, Rehak M, Wolf A, Berk H, Eter N, Lang GE, Pielen A, Schmitz-Valckenberg S, Quiering C, Rose U, Hoerauf H; COMRADE Study Group. Feltgen N, et al. Among authors: quiering c. Acta Ophthalmol. 2018 Dec;96(8):e933-e941. doi: 10.1111/aos.13770. Epub 2018 May 31. Acta Ophthalmol. 2018. PMID: 29855153 Free article. Clinical Trial.
Ranibizumab Pro Re nata versus Dexamethasone in the Management of Ischemic Retinal Vein Occlusion: Post-hoc Analysis from the COMRADE Trials.
Pielen A, Feltgen N, Hattenbach LO, Hoerauf H, Bertelmann T, Quiering C, Vögeler J, Priglinger S, Lang GE, Schmitz-Valckenberg S, Wolf A, Rehak M. Pielen A, et al. Among authors: quiering c. Curr Eye Res. 2020 May;45(5):604-614. doi: 10.1080/02713683.2019.1679839. Epub 2019 Oct 31. Curr Eye Res. 2020. PMID: 31665935 Free article. Clinical Trial.
Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy - The non-interventional second year follow-up to the PRIDE study.
Lang GE, Stahl A, Voegeler J, Quiering C, Zaremba L, Lorenz K, Spital G, Liakopoulos S. Lang GE, et al. Among authors: quiering c. Acta Ophthalmol. 2022 Mar;100(2):e578-e587. doi: 10.1111/aos.14907. Epub 2021 Jun 14. Acta Ophthalmol. 2022. PMID: 34121335 Free article.
A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study.
Holz FG, Schmitz-Valckenberg S, Wolf A, Agostini H, Lorenz K, Pielen A, Feltgen N, Guthoff R, Quiering C, Clemens A, Jaeger K. Holz FG, et al. Among authors: quiering c. Graefes Arch Clin Exp Ophthalmol. 2022 Aug;260(8):2695-2702. doi: 10.1007/s00417-022-05591-z. Epub 2022 Feb 21. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 35188581 Free PMC article. Clinical Trial.
Prevalence of Back Pain among German Ophthalmologists.
Bertelmann T, Heutelbeck A, Bopp S, Sagebiel LL, Eichberg S, Hallier E, Hilgers R, Quiering C, Hoerauf H. Bertelmann T, et al. Among authors: quiering c. Ophthalmic Res. 2021;64(6):974-982. doi: 10.1159/000517574. Epub 2021 Jul 22. Ophthalmic Res. 2021. PMID: 34348327 Free article.
12 results